SMARCA5 Antibody

What is SMARCA5 and why is it significant in chromatin remodeling research?

SMARCA5 is a 121.9 kDa nuclear protein belonging to the SNF2/RAD54 helicase family that functions as the ATPase motor of the ISWI chromatin remodeler complex . It plays essential roles in regulating chromatin structure and accessibility, directly impacting gene expression programs critical for development and cellular functions. The significance of SMARCA5 stems from its fundamental involvement in establishing chromatin architecture, facilitating DNA-dependent processes including transcription, replication, and DNA repair. Recent studies have revealed SMARCA5's crucial functions in neurodevelopment, with pathogenic variants causing a previously unidentified neurodevelopmental disorder characterized by mild developmental delay, postnatal short stature, and microcephaly . Additionally, SMARCA5 has emerged as a key regulator of B cell immune responses, controlling genes essential for germinal center formation and antibody-secreting cell differentiation .

Which detection methods are most effective when using SMARCA5 antibodies?

For SMARCA5 detection, Western blotting and immunofluorescence represent the most validated and reliable techniques. Commercial SMARCA5 antibodies have been optimized for these applications, with recommended dilutions typically around 1 μg/mL for Western blot analysis . Immunohistochemistry has also proven effective, particularly for detecting nuclear localization of SMARCA5 in tissue samples, as demonstrated in human spleen tissue where specific staining is localized to nuclei in splenocytes . When employing immunofluorescence, heat-induced epitope retrieval is often necessary to unmask antigens in fixed tissues. For Western blotting, researchers should account for SMARCA5's high molecular weight (~121.9 kDa) when selecting gel concentrations and transfer conditions . Multi-method validation is strongly recommended, as combining techniques like Western blotting with immunofluorescence provides more robust experimental evidence of SMARCA5 expression and localization.

How should researchers validate the specificity of SMARCA5 antibodies?

Validating SMARCA5 antibody specificity requires a multi-step approach to ensure experimental reliability. First, perform Western blot analysis to confirm detection of a single band at approximately 121.9 kDa, corresponding to SMARCA5's predicted molecular weight . Include both positive control samples (tissues with known SMARCA5 expression such as spleen) and negative controls (samples where SMARCA5 is knocked down or absent) . Testing antibody performance across multiple cell types is recommended, as SMARCA5 is ubiquitously expressed across tissues . For immunofluorescence or immunohistochemistry, confirm nuclear localization pattern, as SMARCA5 is predominantly nuclear . Cross-validation with multiple antibodies targeting different epitopes of SMARCA5 provides additional confidence in specificity. When possible, include genetic controls such as SMARCA5 knockdown/knockout samples, which should show significant reduction in signal intensity. RNA-protein correlation studies comparing SMARCA5 protein levels (detected by antibody) with mRNA expression can further validate antibody specificity and performance in experimental systems.

How does SMARCA5 antibody performance differ in detecting various isoforms or post-translational modifications?

SMARCA5 antibody selection requires careful consideration of isoform specificity and post-translational modification (PTM) detection capabilities. Commercial antibodies typically target the canonical SMARCA5 protein (1052 amino acids, 121.9 kDa) , but may exhibit variable affinity for alternatively spliced isoforms. When investigating specific PTMs, researchers should select antibodies that either detect the unmodified protein regardless of modification state or those specifically targeting the modification of interest . For studying SMARCA5's chromatin remodeling functions, antibodies recognizing the functional domains (such as the ATPase domain or the HSS domain containing the acidic patch binding motif) may provide more mechanistic insights . The acidic patch binding (APB) motif, which includes the functionally critical Arg736 residue, is particularly important for SMARCA5's nucleosome sliding activity . When investigating potential disease-associated variants (such as those affecting the APB motif), researchers should confirm whether their chosen antibody's epitope overlaps with these regions, as structural modifications might alter antibody recognition. Mass spectrometry analysis combined with immunoprecipitation can help identify which modifications are preserved or detected by specific antibodies.

What are the optimal protocols for immunoprecipitation of SMARCA5-associated chromatin complexes?

For successful immunoprecipitation of SMARCA5-associated chromatin complexes, researchers should implement specialized chromatin immunoprecipitation (ChIP) protocols accounting for SMARCA5's role as a chromatin remodeler. Begin with crosslinking using 1% formaldehyde for 10-15 minutes at room temperature to preserve protein-DNA interactions . For SMARCA5 specifically, dual crosslinking (using both formaldehyde and protein-specific crosslinkers like DSG) may improve complex stability and yield. Chromatin fragmentation should be optimized to fragments ranging from 200-500bp, typically achieved through sonication. The immunoprecipitation step is critical; use 3-5 μg of validated SMARCA5 antibody per reaction, and incubate overnight at 4°C with rotation . For analyzing SMARCA5-dependent accessibility changes, consider comparing results with ATAC-seq data, as seen in studies examining SMARCA5's role in B cell activation, where 11,882 peaks showed differential accessibility in control cells versus only 1,168 peaks in SMARCA5-deficient cells . When investigating protein interactions, stringent washing conditions may disrupt weak interactions, so buffer composition should be carefully optimized. For confirming the specificity of SMARCA5 chromatin associations, sequential ChIP (Re-ChIP) with antibodies against known SMARCA5 complex members can validate authentic interactions.

How can researchers effectively utilize SMARCA5 antibodies to investigate its role in neurodevelopmental disorders?

To investigate SMARCA5's role in neurodevelopmental disorders, researchers should implement a multi-faceted approach combining genetic analysis with functional studies. Start by establishing appropriate cellular and animal models that recapitulate the specific SMARCA5 variants identified in patient cohorts, such as the de novo or dominantly segregating rare heterozygous variants associated with developmental delay, postnatal short stature, and microcephaly . For immunohistochemical analysis of brain tissues, use SMARCA5 antibodies at optimized concentrations (10 μg/mL has been effective in human tissues) with appropriate heat-induced epitope retrieval . When examining neuronal morphology and dendritic complexity, as demonstrated in Drosophila models with loss of Iswi (SMARCA5 ortholog), combine SMARCA5 immunostaining with neuronal markers to assess both expression and morphological consequences . Chromatin accessibility studies comparing wild-type and mutant SMARCA5 conditions should employ ChIP-seq or ATAC-seq approaches; the latter has revealed substantial differences in accessibility patterns in other SMARCA5-dependent contexts . For rescue experiments, validate antibody detection of both wild-type and mutant SMARCA5 proteins to ensure comparable expression levels between conditions. When analyzing patient-derived cells, SMARCA5 antibodies can help determine whether specific variants affect protein stability, nuclear localization, or interaction with chromatin and binding partners.

What methodological approaches enable the study of SMARCA5's role in B cell immune responses?

Investigating SMARCA5's role in B cell immune responses requires specialized immunological techniques combined with careful antibody selection. Researchers should consider adoptive transfer models using antigen-specific B cells (such as the B1-8hi system for NP-antigen responses) from SMARCA5-deficient and control mice to track cell fate during immune responses . Flow cytometric analysis using SMARCA5 antibodies alongside B cell activation markers (CD86, GL7) and germinal center markers can provide insights into how SMARCA5 deficiency affects specific B cell populations during the immune response . Two-photon laser scanning microscopy has revealed that SMARCA5-deficient B cells fail to generate germinal center structures by day 7 post-immunization, despite showing early activation responses . For mechanistic studies, combine SMARCA5 antibody-based ChIP-seq with ATAC-seq to correlate SMARCA5 binding with changes in chromatin accessibility at genes controlling B cell activation and differentiation. Multiome techniques that simultaneously assess chromatin accessibility and gene expression at the single-cell level are particularly powerful for dissecting SMARCA5's functions, as demonstrated in studies showing dramatic differences in accessibility profiles between control (11,882 differential peaks) and SMARCA5-deficient (1,168 differential peaks) B cells . For tracking antibody production, researchers should monitor both total and antigen-specific antibody secreting cells and correlate this with SMARCA5 expression levels.

How can researchers accurately quantify SMARCA5 expression levels across different tissues and cell types?

Accurate quantification of SMARCA5 expression requires a combination of protein and mRNA detection methods for comprehensive analysis. For protein-level quantification, Western blotting with validated SMARCA5 antibodies (used at approximately 1 μg/mL) provides relative expression data when normalized to appropriate housekeeping proteins . Multiple reference proteins should be tested to identify those showing consistent expression across the tissues being compared. Quantitative immunohistochemistry or immunofluorescence enables spatial analysis of SMARCA5 expression within tissue architecture, particularly important for heterogeneous tissues like spleen, where SMARCA5 shows nuclear localization in specific cell populations . For absolute quantification, develop standard curves using purified recombinant SMARCA5 protein (such as E. coli-derived recombinant human SMARCA5/SNF2H fragments) . At the mRNA level, quantitative RT-PCR targeting conserved regions of SMARCA5 transcripts provides a complementary measure of expression. For deeper analysis, RNA-seq or single-cell RNA-seq can reveal cell type-specific expression patterns and potential correlation with differentiation states. Recent translatome analysis using ribosomal pull-down methods has proven particularly valuable for assessing SMARCA5 translation in specific cell populations, revealing high translation levels in germinal center B cells . When investigating disease states, compare SMARCA5 levels between affected and unaffected tissues to identify potential alterations associated with pathological conditions.

What are the technical considerations when using SMARCA5 antibodies in multiplexed imaging applications?

Multiplexed imaging with SMARCA5 antibodies requires careful optimization to achieve reliable co-detection with other proteins of interest. Begin by selecting SMARCA5 antibodies from different host species than other target antibodies to avoid cross-reactivity issues . If using same-species antibodies, consider directly conjugated antibodies or sequential staining protocols with intermediate blocking steps. For tissue sections, standardize antigen retrieval conditions; basic antigen retrieval reagents have proven effective for SMARCA5 detection in paraffin-embedded tissues . When designing panels, account for SMARCA5's predominantly nuclear localization when selecting complementary markers with distinct subcellular distributions . In multiplexed immunofluorescence, carefully optimize signal amplification methods (such as tyramide signal amplification) to prevent signal bleed-through while maintaining detection sensitivity. For advanced applications like imaging mass cytometry or multiplexed ion beam imaging, validate SMARCA5 antibody performance under the specific fixation and preparation protocols required by these techniques. When studying SMARCA5 in the context of chromatin remodeling complexes, co-staining with antibodies against known interaction partners can provide valuable insights into complex formation and localization. Spectral imaging and linear unmixing approaches may be necessary to resolve closely overlapping fluorophore emissions in highly multiplexed panels. Control experiments should include single-color controls, fluorescence-minus-one controls, and biological controls (such as SMARCA5-deficient samples) to validate staining specificity in the multiplexed context.

What are common technical challenges when using SMARCA5 antibodies and how can they be addressed?

Researchers frequently encounter several technical challenges when working with SMARCA5 antibodies. High molecular weight proteins like SMARCA5 (121.9 kDa) often exhibit inefficient transfer during Western blotting, resulting in weak signal intensity . To address this, extend transfer times or use specialized transfer systems designed for high molecular weight proteins, and verify transfer efficiency using reversible protein stains prior to blocking. Nuclear proteins like SMARCA5 can present extraction difficulties; use specialized nuclear extraction buffers containing appropriate detergents and salt concentrations to effectively solubilize chromatin-bound SMARCA5 . For immunohistochemical applications, insufficient epitope retrieval frequently causes false-negative results; optimize antigen retrieval methods, with basic antigen retrieval reagents (such as Catalog # CTS013) having proven effective for SMARCA5 detection in paraffin-embedded tissues . Background staining in immunofluorescence applications can be minimized by implementing additional blocking steps with both serum matching the secondary antibody host and bovine serum albumin. When signal intensity is low despite confirmed SMARCA5 expression, consider signal amplification methods such as biotin-streptavidin systems or tyramide signal amplification. For immunoprecipitation applications, weak pull-down efficiency might indicate epitope masking within protein complexes; test antibodies recognizing different SMARCA5 epitopes or adjust crosslinking conditions to preserve accessibility of the target epitope.

How should researchers interpret discrepancies between SMARCA5 antibody results and genetic or functional data?

When encountering discrepancies between SMARCA5 antibody results and genetic or functional data, researchers should implement a systematic evaluation approach. First, verify antibody specificity through multiple validation methods, including Western blotting to confirm detection of a single band at the expected molecular weight (121.9 kDa) and testing in SMARCA5 knockdown or knockout systems . Consider epitope accessibility issues; some antibodies may fail to detect SMARCA5 when it is engaged in specific protein complexes or bound to chromatin. The acidic patch binding motif, which includes the functionally critical Arg736 residue, represents a region where structural changes might affect antibody recognition while significantly impacting function . When genetic models show phenotypes not reflected in antibody-based assays, investigate potential compensatory mechanisms involving related proteins like other SWI/SNF complex members. For discrepancies between protein levels and phenotypic consequences, consider that even partial reduction in SMARCA5 function may be sufficient to cause significant effects, as demonstrated in B cell studies where SMARCA5 deficiency severely impaired germinal center formation and antibody-secreting cell differentiation despite some protein retention . When mutations affect SMARCA5 function without altering protein levels, functional assays like nucleosome sliding assays may be more informative than simple expression analysis . For complex phenotypes like those observed in neurodevelopmental disorders, combine antibody-based detection with functional assays assessing parameters like dendritic complexity, neuronal migration, or chromatin accessibility to gain a more comprehensive understanding of SMARCA5's role .

How can single-cell multiomics approaches utilizing SMARCA5 antibodies advance our understanding of chromatin regulation?

Single-cell multiomics approaches incorporating SMARCA5 antibodies offer unprecedented insights into chromatin regulation heterogeneity. By combining single-cell ATAC-seq with antibody-based protein detection (CITE-seq or similar methods), researchers can correlate SMARCA5 protein levels directly with chromatin accessibility patterns at the single-cell level . Recent studies have already demonstrated the power of multiome techniques in revealing SMARCA5-dependent accessibility changes during B cell activation, identifying 11,882 peaks with differential accessibility in control cells compared to only 1,168 peaks in SMARCA5-deficient cells . These approaches can be extended to interrogate how SMARCA5 levels correlate with accessibility at specific genomic regions across developmental trajectories or disease progression. Single-cell CUT&Tag approaches utilizing SMARCA5 antibodies would enable mapping of SMARCA5 binding sites in relation to chromatin state and gene expression in heterogeneous cell populations. For neurodevelopmental contexts, where SMARCA5 variants cause specific disorders, single-cell multiomics could reveal cell type-specific consequences of SMARCA5 dysfunction during brain development . When implementing these approaches, researchers should validate SMARCA5 antibody specificity in the specific fixation and permeabilization conditions required by single-cell protocols. Analysis frameworks incorporating gene ontology evaluations, as applied in recent studies showing SMARCA5-accessible regions enriched for leukocyte activation and differentiation processes, can help identify the functional significance of SMARCA5-regulated genomic regions . Integration of data from different modalities requires sophisticated computational approaches to align and correlate SMARCA5 binding, chromatin accessibility, and gene expression at single-cell resolution.

What potential exists for SMARCA5 antibodies in therapeutic development for SMARCA5-associated disorders?

While SMARCA5 antibodies primarily serve research purposes currently, they hold potential for therapeutic development for SMARCA5-associated disorders through multiple pathways. For diagnostic applications, SMARCA5 antibodies could help identify patients with altered SMARCA5 expression or localization associated with the neurodevelopmental syndrome characterized by mild developmental delay, postnatal short stature, and microcephaly . In therapeutic development pipelines, these antibodies are essential tools for validating target engagement of small molecules designed to modulate SMARCA5 activity or interactions. Researchers developing therapeutics for SMARCA5-associated disorders should focus on functional modulation rather than simple expression changes, as recent studies in Drosophila models demonstrated that wild-type SMARCA5 but not mutant variants could rescue neurological phenotypes associated with Iswi loss of function . For targeting SMARCA5 in specific diseases, antibody-drug conjugates or proteolysis-targeting chimeras (PROTACs) could potentially be developed, though such approaches would require extensive optimization of cellular delivery mechanisms given SMARCA5's nuclear localization . Antibodies recognizing specific conformational states of SMARCA5 could potentially distinguish between active and inactive forms, providing valuable biomarkers for treatment response. For immunological applications, given SMARCA5's critical role in B cell responses and germinal center formation, SMARCA5-targeted therapies could potentially modulate antibody responses in autoimmune conditions . As with many chromatin regulators, developing high-specificity approaches that avoid disrupting essential cellular functions remains a significant challenge requiring careful optimization and validation.